eNauka - pregled

Pregled prema Autor Boehnke, Axel

Prikaz rezultata 1 do 6 od 6
GodinaNaslovAutor(i)Tip rezultataMp-kat.
2017Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialDavies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem;
Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David;
Naučni članak
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+
2012Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with FollicDavies, Andrew J; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, Martin; Macdonald, DavidConference Paper
Mp. category will be shown later
2013Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicDavies, AJ; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, M; MacDonald, DKonferencijski rad
Mp kategorija će biti prikazana naknadno.
2014Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyDavies, Andrew; Merli, Francesco; Mihaljević, Biljana ; Siritanaratkul, Noppadol; Solal-Céligny, Phillippe; Barrett, Martin; Berge, Claude; Bittner, Beate; Boehnke, Axel; McIntyre, Christine;
MacDonald, David;
Article
21a+M21a+
2014Subcutaneous Rituximab and Chemotherapy Achieves Similar Overall Response Rates to Intravenous Rituximab in First-Line Follicular Lymphoma: Efficacy and Safety Results of the Phase Iii Sabrina StudyDavies, A; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Cambon, N; Macgregor, L; Brewster, M;
Barrett, M; MacDonald, D;
Conference Paper
Mp. category will be shown later
2013Subcutaneous Rituximab and Chemotherapy Achieves Similar Trough Levels, Safety, and Response as Intravenous Rituximab in First-Line Follicular Lymphoma: Stage 1 Results of the Phase 3 Sabrina StudyDavies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, Martin; Macdonald, DavidConference Paper
Mp. category will be shown later